GLOBAL EPINEPHRINE AUTOINJECTOR MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Epinephrine Autoinjector Market, By Type (0.15mg, 0.3mg, 0.5mg), By End User (Hospitals, Clinics, Individual Customers), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Epinephrine Autoinjector Market- Recent Developments

Business Development Activities by the Market Players

On September 20, 2023, the U.S. Food and Drug Administration declined to approve an alternative to epinephrine autoinjectors such as EpiPens, telling the maker of a nasal spray that more study is required. ARS Pharma, a pharmaceutical company that produces the drug, announced that the U.S. FDA had asked for a study to be completed. This study is to evaluate the effects of multiple doses of their spray, known as neffy, in comparison to multiple doses of an epinephrine injection.
On August 10, 2023, Illinois Senate Democrats announced that it has enacted US$ 60 price cap on epinephrine autoinjector two-packs. The cap comes amid an ongoing injector shortage and follows similar moves in other states.
In November, 2021, Pfizer, an American multinational pharmaceutical and biotechnology corporation coordinated with U.S. FDA to extend the expiration dates of specific lots of EpiPen 0.3 mg Auto-Injectors and its authorized generic version after review of stability data. This announcement is based on a careful review of product stability data provided by Pfizer.